Search results

Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older

Type

Highly specialised technologies guidance

Published

22 February 2022

Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged

Type

Highly specialised technologies guidance

Published

20 July 2016

Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Type

Highly specialised technologies guidance

Published

05 May 2022

Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over

Type

Highly specialised technologies guidance

Published

24 November 2021

Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults

Type

Highly specialised technologies guidance

Published

21 October 2020

Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults

Type

Highly specialised technologies guidance

Published

24 February 2021

Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

Type

Highly specialised technologies guidance

Published

28 January 2015

Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies

Type

Highly specialised technologies guidance

Published

07 July 2021

Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages

Type

Highly specialised technologies guidance

Published

20 April 2022

Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children

Type

Highly specialised technologies guidance

Published

28 March 2022

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Type

Highly specialised technologies guidance

Published

22 May 2019

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Type

Highly specialised technologies guidance

Published

10 October 2018

Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency

Type

Highly specialised technologies guidance

Published

07 February 2018

Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

Type

Highly specialised technologies guidance

Published

02 August 2017

Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults

Type

Highly specialised technologies guidance

Published

28 June 2017

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Type

Highly specialised technologies guidance

Published

27 November 2019

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Type

Highly specialised technologies guidance

Published

09 October 2019

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Type

Highly specialised technologies guidance

Published

14 August 2019

Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16

Type

Highly specialised technologies guidance

Published

22 February 2017

Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults

Type

Technology appraisal guidance

Last updated

01 October 2009

Evidence-based recommendations on fulvestrant (Faslodex) for untreated locally advanced or metastatic (secondary) oestrogen-receptor positive breast cancer in

Type

Technology appraisal guidance

Published

31 January 2018

Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture

Type

Technology appraisal guidance

Published

25 May 2022

Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)

Type

Technology appraisal guidance

Published

24 January 2018

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Type

Technology appraisal guidance

Published

26 April 2017

Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis (CBC / cirrhosis) in adults

Type

Technology appraisal guidance

Published

26 April 2017

NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy

Type

Technology appraisal guidance

Published

24 May 2017

Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns

Type

Technology appraisal guidance

Published

16 August 2017

Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary

Type

Technology appraisal guidance

Last updated

01 March 2010

NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was

Type

Technology appraisal guidance

Published

22 March 2017

NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was

Type

Technology appraisal guidance

Published

22 March 2017

NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung

Type

Technology appraisal guidance

Published

22 March 2017

NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia

Type

Technology appraisal guidance

Published

22 March 2017

NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Type

Technology appraisal guidance

Published

29 March 2017

Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12

Type

Technology appraisal guidance

Published

28 November 2007

Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults

Type

Technology appraisal guidance

Published

26 July 2006

Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease

Type

Technology appraisal guidance

Published

09 January 2019

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Type

Technology appraisal guidance

Published

13 March 2019

Evidence-based recommendations on autologous chondrocyte implantation (ACI) using chondrosphere (Spherox) for symptomatic articular knee cartilage defects

Type

Technology appraisal guidance

Published

07 March 2018

Evidence-based recommendations on lesinurad (Zurampic) for treating chronic hyperuricaemia (too much uric acid/urate in blood) in adults with gout

Type

Technology appraisal guidance

Published

07 February 2018

Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults

Type

Technology appraisal guidance

Published

15 November 2017

Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee

Type

Technology appraisal guidance

Published

04 October 2017

Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in adults and children aged 2 months and over.

Type

Technology appraisal guidance

Published

16 December 2021

Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms in myelofibrosis in adults

Type

Technology appraisal guidance

Published

16 December 2021

Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults

Type

Technology appraisal guidance

Published

18 April 2018

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Type

Technology appraisal guidance

Published

28 March 2018

Evidence-based recommendations on ixazomib (Ninlaro), with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults

Type

Technology appraisal guidance

Published

07 February 2018

Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis in adults

Type

Technology appraisal guidance

Published

10 January 2018